LAVAL, QC, Jan. 4, 2018 /CNW/ - BELLUS Health Inc.
(TSX: BLU) ("BELLUS Health" or the "Company"), a biopharmaceutical
development company advancing novel therapeutics for conditions
with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and
Chief Executive Officer, will provide a corporate overview of the
Company, including BLU-5937, its lead program for chronic cough, at
the upcoming Biotech Showcase™ 2018 Conference on Tuesday,
January 9 at 9:30 am PT
(12:30 pm ET) in San Francisco, CA, at the Hilton San Francisco
Union Square.
The presentation will be webcast live and will remain available
for three months thereafter on the following
link: https://event.webcasts.com/starthere.jsp?ei=1176848&tp_key=b56a86dfad.
BELLUS Health's presentation will also be available on the
Company's website at www.bellushealth.com following the event.
Biotech Showcase™ is an investor and networking conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives in one place during
the course of one of the industry's largest annual healthcare
investor conferences. Investors and biopharmaceutical executives
from around the world gather in San
Francisco during this bellwether week which sets the tone
for the coming year.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a biopharmaceutical development company
advancing novel therapeutics for conditions with high unmet medical
need. Its pipeline of projects includes the Company's lead drug
candidate BLU-5937 for chronic cough and several other partnered
clinical-stage drug development programs. BLU-5937, a selective
P2X3 antagonist, has the potential to be a best-in-class
therapeutic for chronic cough patients who do not respond to
current therapies. Chronic cough is a cough that lasts more than
eight weeks and is associated with significant adverse social,
psychosocial and physical effects on quality of life. A recent
commercial assessment performed by Torreya Insights on behalf of
the Company concluded that, in the United
States alone, more than 26 million adults have chronic cough
and more than 2.6 million of these patients suffer from refractory
chronic cough lasting for more than a year.
Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations. Such
statements, based as they are on the current expectations of
management, inherently involve numerous important risks,
uncertainties and assumptions, known and unknown, many of which are
beyond BELLUS Health Inc.'s control. Such risks factors include but
are not limited to: the ability to expand and develop its project
pipeline, the ability to obtain financing, the impact of general
economic conditions, general conditions in the pharmaceutical
industry, changes in the regulatory environment in the
jurisdictions in which BELLUS Health Inc. does business, stock
market volatility, fluctuations in costs, changes to the
competitive environment due to consolidation, achievement of
forecasted burn rate, potential payments/outcomes in relation to
indemnity agreements and contingent value rights, achievement of
forecasted pre-clinical and clinical trial milestones and that
actual results may vary once the final and quality-controlled
verification of data and analyses has been completed. In addition,
the length of BELLUS Health Inc.'s drug candidates' development
process, their market size and commercial value, as well as the
sharing of proceeds between BELLUS Health Inc. and its potential
partners from potential future revenues, if any, are dependent upon
a number of factors. Consequently, actual future results and events
may differ materially from the anticipated results and events
expressed in the forward-looking statements. The Company believes
that expectations represented by forward-looking statements are
reasonable, yet there can be no assurance that such expectations
will prove to be correct. The reader should not place undue
reliance, if any, on any forward-looking statements included in
this news release. These forward-looking statements speak only as
of the date made, and BELLUS Health Inc. is under no obligation and
disavows any intention to update publicly or revise such statements
as a result of any new information, future event, circumstances or
otherwise, unless required by applicable legislation or regulation.
Please see BELLUS Health Inc.'s public filings with the
Canadian securities regulatory authorities, including the Annual
Information Form, for further risk factors that might affect BELLUS
Health Inc. and its business.
SOURCE BELLUS Health Inc.